Skip to main content
. 2022 Feb 13;14(4):933. doi: 10.3390/cancers14040933

Figure 1.

Figure 1

Clinical outcomes after stereotactic body radiotherapy in all eligible tumors and patients. Cumulative rate of local control (LC), progression free survival (PFS), and overall survival (OS) are shown. (A) The 1-, 3-, and 5-year LC rates are 95.7%, 87.7%, and 87.7%, respectively. (B) The 1-, 3-, and 5-year PFS rates are 75.6%, 47.2%, and 32.4%, respectively. (C) The 1-, 3-, and 5-year OS rates are 85.6%, 62.2%, and 47.2%, respectively.